About this document
Secukinumab by Dr. Hadika Pramana, SpPD is a document available to read on EtoBox.
This study evaluated the long-term effectiveness of secukinumab (SCK) in treating axial spondyloarthritis (AxSpA) using a cohort of 39 patients from three Italian hospitals over 2 years. AxSpA is a chronic inflammatory disease affecting the spine and sacroiliac joints. The study found that both the BASDAI and ASDAS-CRP scores, which measure disease activity, significantly decreased over the observation period. By the end, 78.2% of patients remained on SCK treatment. There were no significant differences in
- Author
- Dr. Hadika Pramana, SpPD
- Language
- EN